Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals Broadens Management Team and Expands Product Advisory Board

Concert Pharmaceuticals Broadens Management Team and Expands Product Advisory Board

December 9, 2009

LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. announced today the appointment of Lijun Wu, Ph.D., as Vice President, Biology. In this newly created position, Dr. Wu will have responsibility for Concert’s non-clinical pharmacology, pharmacokinetics, drug metabolism, and bioanalytical functions and will report to Roger Tung, Ph.D., President and Chief Executive Officer of Concert.

Novomer, Inc.

Novomer Expands Green Materials Commercialization With Kodak, RIT and NYSERDA

Novomer Expands Green Materials Commercialization With Kodak, RIT and NYSERDA

December 14, 2009

$800,000 New York State Funding Set to Create Green Jobs, Increase Manufacturing and Reduce Dependency on Petroleum-Based Plastics

AVEO Pharmaceuticals, Inc.

AVEO Pharmaceuticals Files Registration Statement for Initial Public Offering

AVEO Pharmaceuticals Files Registration Statement for Initial Public Offering

December 16, 2009

CAMBRIDGE, Mass., December 16, 2009—AVEO Pharmaceuticals, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to the proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined.

Acceleron Pharma, Inc.

Acceleron Pharma Expands Management Team with Two New Appointments

Acceleron Pharma Expands Management Team with Two New Appointments

December 22, 2009

Key Personnel Support Growth and Advancement of Clinical Pipeline and GMP Manufacturing Activities

Novomer, Inc.

Novomer highlighted as #1 in GreanBeat's 2009’s top 9 forward-looking cleantech investments

Novomer highlighted as #1 in GreanBeat's 2009’s top 9 forward-looking cleantech investments

December 31, 2009

1. Novomer — In April, Novomer, a company that sequesters carbon dioxide emissions from coal-fired plants and other sources in biodegradable plastic consumer products, brought in $14 million ... has the opportunity to capture a vast amount of carbon that would otherwise be released into the atmosphere while cheaply making plastic products that don’t require as much petroleum. It’s basically greening two businesses at once.

T2 Biosystems, Inc.

T2 BioSystems Appoints Ken Toso Vice President, Product Development

T2 BioSystems Appoints Ken Toso Vice President, Product Development

January 6, 2010

Company Preparing for Commercial Evaluation and Launch

Ensemble Therapeutics Corporation

Ensemble Discovery Initiates Collaboration with Pfizer to Develop Novel Drugs against Protein-Protein Interaction Targets

Ensemble Discovery Initiates Collaboration with Pfizer to Develop Novel Drugs against Protein-Protein Interaction Targets

January 6, 2010

Second Major Alliance Validates Ensemble Leadership in New Therapeutic Space

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ensemble Discovery today announced the initiation of a strategic alliance with Pfizer Inc. (NYSE: PFE) to discover and develop drug candidates of a novel class against a number of high-value pharmaceutical targets.

Mascoma Corporation

Mascoma Appoints William J. Brady as Chief Executive Officer

Mascoma Appoints William J. Brady as Chief Executive Officer

January 7, 2010

New Leadership Reflects Company’s Transition into Commercial Operations

Lebanon, New Hampshire – January 7, 2010: Mascoma Corporation today announced the appointment of William J. Brady as the new Chief Executive Officer, effective immediately. Mr. Brady will also join the Boards of Directors of Mascoma and Frontier Renewable Resources, LLC. With twenty-three years of experience at Cabot Corporation, a chemical industry leader, Bill is poised to lead Mascoma into full commercial operations.

BIND Therapeutics, Inc.

BIND Biosciences Appoints Scott Minick as President and CEO

BIND Biosciences Appoints Scott Minick as President and CEO

January 11, 2010

CAMBRIDGE, Mass. - (Business Wire) BIND Biosciences announced today the appointment of Scott Minick as President and CEO. Mr. Minick was formerly a Managing Director at ARCH Venture Partners, a major BIND investor, and previously the President and COO of SEQUUS Pharmaceuticals/Liposome Technology Inc., where he led the company during its 1995 FDA approval and successful commercial launch of the leading oncology drug, Doxil (liposomal doxorubicin). SEQUUS was subsequently acquired by ALZA for $580 MM.

BIND Therapeutics, Inc.

BIND Biosciences, Inc. Closes $11M Series C Financing Round

BIND Biosciences, Inc. Closes $11M Series C Financing Round

January 14, 2010

High-Precision Therapeutics through Medicinal Nanoengineering™